StockDuty ← Dashboard Aug 17, 2026 07:03 AM ET
SignalFDA/Bio

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Positive Phase 3 topline results signal regulatory approval potential for efgartigimod in myositis.

What changed
Why it matters
Positive Phase 3 topline results signal regulatory approval potential for efgartigimod in myositis.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →